Kangmei Pharmaceutical Co Ltd Total Assets
Kangmei Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Kangmei Pharmaceutical Co Ltd (600518) holds total assets worth CN¥13.68 Billion CNY (≈ $2.00 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 600518 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Kangmei Pharmaceutical Co Ltd (1997–2024)
Total assets of Kangmei Pharmaceutical Co Ltd from 1997 to 2024. This chart illustrates how Kangmei Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Kangmei Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Kangmei Pharmaceutical Co Ltd - Asset Composition Analysis
Kangmei Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Kangmei Pharmaceutical Co Ltd total assets breakdown as of December 2024. Kangmei Pharmaceutical Co Ltd's total assets of CN¥13.68 Billion consist of 50.0% current assets and 50.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.1% |
| Accounts Receivable | CN¥3.05 Billion | 22.1% |
| Inventory | CN¥2.51 Billion | 18.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥409.47 Million | 3.0% |
| Goodwill | CN¥106.35 Million | 0.8% |
Asset Composition Trend (1997–2024)
This chart illustrates how Kangmei Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Kangmei Pharmaceutical Co Ltd (600518) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kangmei Pharmaceutical Co Ltd's current assets represent 50.0% of total assets in 2024, an increase from 34.7% in 1997.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, up from 1.8% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 10.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.
Kangmei Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Kangmei Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Kangmei Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 1.43 | 0.80 |
| Quick Ratio | 0.79 | 0.84 | 0.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.22 Billion | CN¥2.10 Billion | CN¥-4.74 Billion |
Kangmei Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Kangmei Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.64 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | CN¥13.80 Billion |
| Market Capitalization | $2.59 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Kangmei Pharmaceutical Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Kangmei Pharmaceutical Co Ltd's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Kangmei Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual total assets of Kangmei Pharmaceutical Co Ltd from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥13.80 Billion ≈ $2.02 Billion |
-3.38% |
| 2023-12-31 | CN¥14.28 Billion ≈ $2.09 Billion |
-5.50% |
| 2022-12-31 | CN¥15.11 Billion ≈ $2.21 Billion |
-5.87% |
| 2021-12-31 | CN¥16.05 Billion ≈ $2.35 Billion |
-51.83% |
| 2020-12-31 | CN¥33.33 Billion ≈ $4.88 Billion |
-48.40% |
| 2019-12-31 | CN¥64.59 Billion ≈ $9.45 Billion |
-11.70% |
| 2018-12-31 | CN¥73.14 Billion ≈ $10.70 Billion |
+12.03% |
| 2017-12-31 | CN¥65.29 Billion ≈ $9.55 Billion |
+19.10% |
| 2016-12-31 | CN¥54.82 Billion ≈ $8.02 Billion |
+43.87% |
| 2015-12-31 | CN¥38.11 Billion ≈ $5.58 Billion |
+36.68% |
| 2014-12-31 | CN¥27.88 Billion ≈ $4.08 Billion |
+25.29% |
| 2013-12-31 | CN¥22.25 Billion ≈ $3.26 Billion |
+23.91% |
| 2012-12-31 | CN¥17.96 Billion ≈ $2.63 Billion |
+17.86% |
| 2011-12-31 | CN¥15.24 Billion ≈ $2.23 Billion |
+85.64% |
| 2010-12-31 | CN¥8.21 Billion ≈ $1.20 Billion |
+32.03% |
| 2009-12-31 | CN¥6.22 Billion ≈ $909.74 Million |
+47.72% |
| 2008-12-31 | CN¥4.21 Billion ≈ $615.85 Million |
+31.44% |
| 2007-12-31 | CN¥3.20 Billion ≈ $468.53 Million |
+66.58% |
| 2006-12-31 | CN¥1.92 Billion ≈ $281.27 Million |
+143.29% |
| 2005-12-31 | CN¥790.04 Million ≈ $115.61 Million |
-7.49% |
| 2004-12-31 | CN¥853.97 Million ≈ $124.96 Million |
+21.18% |
| 2003-12-31 | CN¥704.69 Million ≈ $103.12 Million |
+11.93% |
| 2002-12-31 | CN¥629.58 Million ≈ $92.13 Million |
+21.63% |
| 2001-12-31 | CN¥517.61 Million ≈ $75.74 Million |
+123.85% |
| 2000-12-31 | CN¥231.23 Million ≈ $33.84 Million |
+1.91% |
| 1999-12-31 | CN¥226.89 Million ≈ $33.20 Million |
+8.91% |
| 1998-12-31 | CN¥208.33 Million ≈ $30.48 Million |
+17.62% |
| 1997-12-31 | CN¥177.12 Million ≈ $25.92 Million |
-- |
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more